Shareholder Sarissa Capital Management LP Has Boosted Achillion Pharmaceuticals (ACHN) Position; Procter & Gamble Co (PG) Holder Essex Financial Services Has Cut Position as Valuation Declined

May 23, 2018 - By Richard Conner

The Procter & Gamble Company (NYSE:PG) Logo

Essex Financial Services Inc decreased its stake in Procter & Gamble Co (PG) by 5.13% based on its latest 2017Q4 regulatory filing with the SEC. Essex Financial Services Inc sold 4,319 shares as the company’s stock declined 15.56% with the market. The institutional investor held 79,793 shares of the package goods and cosmetics company at the end of 2017Q4, valued at $7.33 million, down from 84,112 at the end of the previous reported quarter. Essex Financial Services Inc who had been investing in Procter & Gamble Co for a number of months, seems to be less bullish one the $186.28B market cap company. The stock increased 0.07% or $0.05 during the last trading session, reaching $74.08. About 602,489 shares traded. The Procter & Gamble Company (NYSE:PG) has declined 14.03% since May 23, 2017 and is downtrending. It has underperformed by 25.58% the S&P500.

Alex Denner increased its stake in Achillion Pharmaceuticals Inc (ACHN) by 17% based on its latest 2017Q4 regulatory filing with the SEC. Sarissa Capital Management Lp bought 363,200 shares as the company’s stock rose 28.04% while stock markets declined. The hedge fund run by Alex Denner held 2.50M shares of the health care company at the end of 2017Q4, valued at $7.20M, up from 2.14M at the end of the previous reported quarter. Sarissa Capital Management Lp who had been investing in Achillion Pharmaceuticals Inc for a number of months, seems to be bullish on the $518.78 million market cap company. The stock increased 0.54% or $0.02 during the last trading session, reaching $3.75. About 54,505 shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 2.57% since May 23, 2017 and is downtrending. It has underperformed by 14.12% the S&P500.

More notable recent Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) news were published by: Benzinga.com which released: “The Week Ahead In Biotech: PDUFA Dates, IPOs And More” on May 21, 2018, also Benzinga.com with their article: “23 Stocks Moving In Monday’s Pre-Market Session” published on May 21, 2018, Benzinga.com published: “SMid-Cap Biotech: Barclays Downgrades Prothena, Upgrades Achillion” on May 21, 2018. More interesting news about Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) were released by: Globenewswire.com and their article: “Achillion Announces Upcoming Scientific Presentations at the 55th ERA-EDTA Congress” published on May 11, 2018 as well as Globenewswire.com‘s news article titled: “Achillion Reports First Quarter 2018 Financial Results and Management Transition” with publication date: May 02, 2018.

Among 12 analysts covering Achillion Pharma (NASDAQ:ACHN), 6 have Buy rating, 0 Sell and 6 Hold. Therefore 50% are positive. Achillion Pharma had 28 analyst reports since August 13, 2015 according to SRatingsIntel. The firm has “Buy” rating by Maxim Group given on Thursday, February 25. Maxim Group maintained it with “Buy” rating and $700 target in Wednesday, August 9 report. FBR Capital initiated the stock with “Outperform” rating in Thursday, September 15 report. As per Monday, May 21, the company rating was upgraded by Barclays Capital. The rating was maintained by Robert W. Baird on Monday, September 11 with “Hold”. The firm has “Outperform” rating given on Friday, February 26 by Robert W. Baird. The company was upgraded on Friday, November 4 by Chardan Capital Markets. Chardan Capital Markets initiated Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) rating on Thursday, July 14. Chardan Capital Markets has “Sell” rating and $4 target. Jefferies initiated the stock with “Hold” rating in Wednesday, September 9 report. UBS upgraded Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on Tuesday, September 8 to “Buy” rating.

Investors sentiment increased to 2.08 in Q4 2017. Its up 1.12, from 0.96 in 2017Q3. It improved, as 10 investors sold ACHN shares while 28 reduced holdings. 34 funds opened positions while 45 raised stakes. 110.36 million shares or 4.96% more from 105.14 million shares in 2017Q3 were reported. Bb Biotech Ag owns 1.28 million shares for 0.1% of their portfolio. Numeric Investors Lc holds 0.04% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 1.95 million shares. 1.84 million were reported by Ecor1 Capital Lc. Morgan Stanley has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Arrowmark Colorado Limited accumulated 935,987 shares or 0.03% of the stock. Opaleye holds 440,000 shares. Tekla Capital Ltd holds 616,000 shares or 0.07% of its portfolio. Ing Groep Nv holds 15,300 shares or 0% of its portfolio. The California-based Parallax Volatility Advisers LP has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Connor Clark And Lunn Invest Mngmt Limited stated it has 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Qcm Cayman Ltd accumulated 0.17% or 14,756 shares. Renaissance Limited Co accumulated 2.18 million shares or 0.01% of the stock. Amalgamated Bancorp holds 15,839 shares or 0% of its portfolio. Proshare Advsr Llc, a Maryland-based fund reported 91,640 shares. Great West Life Assurance Co Can invested in 8,721 shares or 0% of the stock.

Analysts await The Procter & Gamble Company (NYSE:PG) to report earnings on July, 26. They expect $0.91 EPS, up 7.06% or $0.06 from last year’s $0.85 per share. PG’s profit will be $2.29 billion for 20.35 P/E if the $0.91 EPS becomes a reality. After $1.00 actual EPS reported by The Procter & Gamble Company for the previous quarter, Wall Street now forecasts -9.00% negative EPS growth.

Among 25 analysts covering Proctor & Gamble (NYSE:PG), 10 have Buy rating, 1 Sell and 14 Hold. Therefore 40% are positive. Proctor & Gamble had 89 analyst reports since August 4, 2015 according to SRatingsIntel. The rating was initiated by Sterne Agee CRT on Tuesday, July 21 with “Neutral”. The stock of The Procter & Gamble Company (NYSE:PG) has “Hold” rating given on Thursday, October 5 by SunTrust. The rating was downgraded by Vetr on Friday, August 7 to “Strong-Buy”. The firm has “Equal-Weight” rating by Morgan Stanley given on Tuesday, October 24. The firm has “Buy” rating by Jefferies given on Tuesday, October 3. RBC Capital Markets maintained The Procter & Gamble Company (NYSE:PG) on Tuesday, September 5 with “Hold” rating. The firm has “Equal-Weight” rating given on Friday, April 20 by Morgan Stanley. The firm has “Buy” rating by Stifel Nicolaus given on Friday, July 22. The firm has “Neutral” rating by Atlantic Securities given on Wednesday, January 6. Jefferies maintained The Procter & Gamble Company (NYSE:PG) rating on Wednesday, April 19. Jefferies has “Buy” rating and $103 target.

Since February 15, 2018, it had 0 insider purchases, and 6 insider sales for $6.67 million activity. Fish Kathleen B had sold 1,313 shares worth $103,190. 2,075 shares were sold by Bishop Steven D, worth $149,130. Posada Juan Fernando also sold $739,189 worth of The Procter & Gamble Company (NYSE:PG) on Thursday, February 15. Another trade for 8,502 shares valued at $668,179 was made by Pritchard Marc S. on Thursday, February 15.

Essex Financial Services Inc, which manages about $2.52 billion and $420.71 million US Long portfolio, upped its stake in Vanguard World Fds Finls Etf (VFH) by 11,132 shares to 64,952 shares, valued at $4.55 million in 2017Q4, according to the filing. It also increased its holding in Celgene Corp (NASDAQ:CELG) by 3,901 shares in the quarter, for a total of 30,547 shares, and has risen its stake in General Dynamicscorp (NYSE:GD).

Investors sentiment increased to 0.89 in Q4 2017. Its up 0.07, from 0.82 in 2017Q3. It improved, as 64 investors sold PG shares while 740 reduced holdings. 118 funds opened positions while 594 raised stakes. 1.47 billion shares or 1.61% less from 1.50 billion shares in 2017Q3 were reported. Barrett Asset Mgmt Ltd Llc reported 0.91% of its portfolio in The Procter & Gamble Company (NYSE:PG). Bell Bank & Trust owns 39,127 shares for 1.01% of their portfolio. Cliftonlarsonallen Wealth Advsr Limited Liability Co owns 0.11% invested in The Procter & Gamble Company (NYSE:PG) for 11,553 shares. Berkshire Asset Pa has 207,520 shares. Legacy Cap Ptnrs accumulated 48,370 shares or 2.2% of the stock. Bank Hapoalim Bm owns 12,915 shares or 0.26% of their US portfolio. Moreover, First Republic Investment Mngmt has 1.13% invested in The Procter & Gamble Company (NYSE:PG). Hallmark Mgmt owns 29,721 shares for 0.33% of their portfolio. Hennessy Advisors reported 0.17% stake. Credit Agricole S A holds 4,511 shares. Vantage Investment Advsrs Lc holds 1.49% of its portfolio in The Procter & Gamble Company (NYSE:PG) for 70,709 shares. Proffitt And Goodson Incorporated invested in 13,584 shares. Fred Alger Mngmt, New York-based fund reported 40,172 shares. Edgewood Mgmt Ltd holds 0% or 2,433 shares. Bank Of Nova Scotia reported 0.68% stake.

The Procter & Gamble Company (NYSE:PG) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>